What foods contain nisin?

Nisin is used in processed cheese, canned foods, meat products, dairy, and some beverages including beer and wine. It is added at concentrations of 1-25 mg/kg, where it is tasteless and odorless. Nisin also occurs naturally in fermented dairy products made with Lactococcus lactis starter cultures. It is listed as E234 on European food labels.

Peptide Antibiotics

Nisin: The Food-Grade Antimicrobial Peptide in Your Cheese

11 min read|March 24, 2026

Peptide Antibiotics

50+ countries

Have approved nisin as a food preservative, making it the most commercially successful antimicrobial peptide in history and the only one with GRAS status from the FDA.

Sugrue et al., Frontiers in Microbiology, 2024

View as image

You have almost certainly eaten nisin. This 34-amino-acid peptide, produced naturally by the bacterium Lactococcus lactis during cheese fermentation, is the most commercially successful antimicrobial peptide in human history. It has been used as a food preservative since 1953, is approved in over 50 countries, and carries GRAS (Generally Recognized as Safe) status from the FDA. Nisin kills Gram-positive bacteria including Listeria, Staphylococcus, Bacillus, and Clostridium through a dual mechanism that no conventional antibiotic matches: it simultaneously blocks cell wall synthesis and punches holes in bacterial membranes. As antibiotic resistance escalates, researchers are now investigating nisin for biomedical applications far beyond food preservation. Among peptide antibiotics, nisin occupies a unique position as the one humans have been consuming safely for decades.

Key Takeaways

Nisin is a 34-amino-acid lantibiotic containing five lanthionine ring structures and uncommon amino acids (dehydroalanine, dehydrobutyrine) that give it exceptional structural stability
It kills bacteria through a dual mechanism: binding lipid II to block cell wall synthesis and forming pores in the cell membrane, a combination no conventional antibiotic replicates
Nisin has been used as a food preservative since 1953 and is the only antimicrobial peptide with FDA GRAS status, approved in over 50 countries
A 2024 review cataloged bacteriocin diversity and identified nisin as the gold standard for food-grade antimicrobial peptides, with activity against Listeria, MRSA, and Clostridium difficile
Beyond food, nisin-loaded delivery systems are being developed for skin infections, oral health, and tissue engineering applications
A 2025 study demonstrated an antibiotic-free combination of nisin with other bacteriocins that killed drug-resistant pathogens without promoting further resistance development

What Is Nisin?

Nisin belongs to a class of antimicrobial peptides called lantibiotics (lanthionine-containing antibiotics). These peptides are produced by Gram-positive bacteria and undergo extensive post-translational modification that gives them unusual structural features not found in standard peptides.

The 34-amino-acid chain of nisin contains five lanthionine ring structures formed by thioether bridges between modified serine/threonine residues and cysteine residues. It also contains dehydroalanine (Dha) and dehydrobutyrine (Dhb), amino acids that are enzymatically created from serine and threonine during biosynthesis. These modifications make nisin structurally rigid, heat-stable (it survives pasteurization), and resistant to many proteases that would destroy conventional peptides.^[1]

Lactococcus lactis, the bacterium that produces nisin, is the same species used in cheese and buttermilk fermentation. Nisin production evolved as a competitive strategy: bacteria that produce it eliminate competing organisms from their environment. Humans co-opted this strategy for food preservation, initially by observing that certain cheese cultures inhibited spoilage organisms.

Two main natural variants exist: nisin A and nisin Z, which differ by a single amino acid at position 27 (histidine in nisin A, asparagine in nisin Z). Nisin Z has slightly higher diffusion in agar, potentially making it more effective in solid food matrices.

The Dual Killing Mechanism

Nisin's antimicrobial activity is exceptional because it targets bacteria through two simultaneous mechanisms.

Lipid II Binding

Lipid II is a membrane-anchored precursor molecule essential for bacterial cell wall (peptidoglycan) synthesis. It is the same target that vancomycin binds, but nisin binds to a different part of the lipid II molecule. The N-terminal rings of nisin (rings A and B) form a cage-like structure that captures the pyrophosphate group of lipid II with high specificity.

This binding has two consequences. First, it sequesters lipid II, preventing its incorporation into the growing cell wall and halting peptidoglycan synthesis. Second, the lipid II-nisin complex serves as a docking platform for the second killing mechanism.

Pore Formation

After binding lipid II, nisin's C-terminal region inserts into the bacterial membrane and recruits additional nisin molecules. Eight nisin molecules and four lipid II molecules assemble into a stable pore complex that spans the membrane. These pores are approximately 2 nanometers in diameter, large enough to allow rapid efflux of ions, ATP, amino acids, and other small molecules from the bacterial cytoplasm.

The pore formation is lipid II-dependent, which is why nisin is so selective: it requires the bacterial cell wall precursor to assemble its pore complex. Mammalian cells do not produce lipid II, explaining nisin's safety for human consumption.

This dual mechanism makes resistance development difficult. A bacterium would need to simultaneously alter its lipid II structure (risking cell wall synthesis) and its membrane composition (risking membrane integrity) to resist nisin. Unlike daptomycin, which targets membranes without a specific receptor, nisin's lipid II anchor provides both specificity and a barrier to resistance.^[2]

Food Preservation: 70 Years of Safe Use

Nisin was first used commercially as a food preservative in the UK in 1953. The WHO and FAO approved it for food use in 1969. The FDA granted GRAS status in 1988. It is designated E234 in the European food additive numbering system.

Commercial nisin (sold under brand names like Nisaplin) is used in:

Processed cheese: Prevents growth of Clostridium botulinum spores, the cause of botulism
Canned foods: Allows lower heat processing temperatures while maintaining safety
Meat products: Controls Listeria monocytogenes, a major foodborne pathogen
Beverages: Prevents spoilage by lactic acid bacteria in beer and wine
Dairy products: Extends shelf life by suppressing spoilage organisms

The typical usage level is 1-25 mg/kg of food product. At these concentrations, nisin is tasteless, odorless, and digested by normal gastrointestinal enzymes without systemic absorption.

Beyond Food: Biomedical Applications

Researchers are now exploring nisin for applications that exploit its antimicrobial properties outside of food.

Drug-Resistant Infections

A 2025 study demonstrated an antibiotic-free antimicrobial combination of nisin with other bacteriocins and a peptidoglycan hydrolase that killed drug-resistant pathogens including MRSA and vancomycin-resistant enterococci (VRE). The combination approach eliminated bacteria without conventional antibiotics, suggesting a strategy for treating infections where standard drugs fail.^[3]

A 2026 review of lactic acid bacteria-derived bacteriocins highlighted nisin as a promising antimicrobial strategy against multi-drug resistant pathogens, cataloging its activity against clinical isolates of MRSA, Clostridioides difficile, and Listeria.^[4]

Skin Infections

A 2025 study developed liposomal co-delivery of azithromycin and nisin for skin infections. The dual-loaded liposomes showed synergistic antibacterial activity against S. aureus, with the nisin component providing rapid membrane disruption while azithromycin inhibited protein synthesis. This combination reduced the required dose of each agent.^[5]

Oral Health

A 2025 study formulated nisin-loaded niosomes (non-ionic surfactant vesicles) into fast-disintegrating oral films. The films dissolved in the mouth within seconds, releasing nisin to target oral pathogens. The formulation maintained nisin's antimicrobial activity and showed potential for treating oral infections and periodontal disease.^[6]

Tissue Engineering

A 2024 study developed 3D-printable gelatin/nisin biomaterial inks for antimicrobial tissue engineering scaffolds. The nisin-containing scaffolds maintained antimicrobial activity against S. aureus while supporting cell growth, demonstrating that nisin can be incorporated into biomedical implant materials to prevent infection.^[7]

Enhanced Delivery Systems

A 2025 study developed cell wall-binding protein-armed nanodelivery systems that target nisin directly to bacterial cell surfaces, enhancing its local concentration at the site of action. The controlled-release system improved nisin's antibacterial efficacy compared to free nisin, addressing the short half-life that limits its biomedical utility.^[8]

Nisin in Context: The Bacteriocin Family

Nisin is the most studied member of a large family of bacterial antimicrobial peptides called bacteriocins. A 2024 review cataloged the diversity of bacteriocins, identifying hundreds of distinct peptides produced by different bacterial species. Bacteriocins are classified by structure: Class I includes lantibiotics like nisin; Class II includes non-modified peptides; Class III includes large bacteriolysins.^[9]

A 2026 review further detailed lactic acid bacteria bacteriocin classification, biosynthesis, and health benefits, positioning nisin within a broader family of naturally produced antimicrobial peptides that could serve as alternatives to conventional antibiotics.^[10]

What distinguishes nisin from other bacteriocins is its safety track record. Seventy years of food use in billions of people with no reported adverse effects provides a safety database that no synthetic antimicrobial peptide can match. This history gives nisin a regulatory advantage for biomedical development: it is a known quantity, not a novel chemical entity.

For comparison with other antimicrobial approaches, how gut bacteria produce antimicrobial peptides covers the broader landscape of bacterially-derived antimicrobials, and LL-37 covers the human innate immune system's own antimicrobial peptide. The AMP clinical trials pipeline tracks which antimicrobial peptides are nearest to clinical use, and vancomycin, which shares nisin's lipid II target, illustrates the clinical importance of this mechanism.

The Bottom Line

Nisin is the most commercially successful antimicrobial peptide, with over 70 years of safe use as a food preservative. Its dual mechanism of lipid II binding and pore formation makes resistance development difficult. Beyond food, nisin is being developed for drug-resistant infections, skin infections, oral health, and tissue engineering applications, with its established safety profile providing a regulatory advantage over synthetic antimicrobial peptides.

Frequently Asked Questions

Nisin is a 34-amino-acid antimicrobial peptide naturally produced by Lactococcus lactis, the same bacterium used to make cheese. It has been used as a food preservative since 1953 and has FDA GRAS status, meaning it is Generally Recognized as Safe. It is approved in over 50 countries and has been consumed by billions of people with no reported adverse effects. Digestive enzymes break nisin down in the gastrointestinal tract without systemic absorption.

Nisin uses a dual mechanism. First, it binds lipid II, a molecule essential for bacterial cell wall synthesis, blocking peptidoglycan construction. Second, it uses the lipid II-nisin complex to form pores in the bacterial membrane, causing rapid leakage of ions and essential molecules. This dual attack makes resistance development difficult because bacteria would need to alter both their cell wall precursor and membrane composition simultaneously.

Preclinical research shows promise. Nisin is active against MRSA, vancomycin-resistant enterococci, and Clostridioides difficile in laboratory studies. A 2025 study showed that combining nisin with other bacteriocins killed drug-resistant bacteria without conventional antibiotics. Nisin-loaded liposomes and nanoparticle delivery systems are being developed for clinical applications, but no nisin-based drug has completed human clinical trials for infection treatment.

Nisin is not classified as a conventional antibiotic. It is a bacteriocin, a class of antimicrobial peptides produced by bacteria to compete with other bacterial species. Unlike antibiotics like penicillin or tetracycline, nisin is used as a food preservative rather than a medicine. Its mechanism of action (lipid II binding and pore formation) differs from most conventional antibiotics, and its food-grade status makes it a unique antimicrobial candidate.

A lantibiotic (lanthionine-containing antibiotic) is a class of antimicrobial peptides produced by Gram-positive bacteria that contain unusual amino acids formed by post-translational modification. These include lanthionine and methyllanthionine, which form thioether ring structures that stabilize the peptide. Nisin, with five lanthionine rings, is the most well-known lantibiotic. The ring structures make lantibiotics heat-stable, protease-resistant, and structurally rigid compared to linear antimicrobial peptides.